Sex differences and serotonergic mechanisms in the behavioural effects of psilocin
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Psilocybin has recently attracted a great deal of attention as a clinical research and therapeutic tool. The aim of this paper is to bridge two major knowledge gaps regarding its behavioural pharmacology – sex differences and the underlying receptor mechanisms. We used psilocin (0.25, 1 and 4 mg/kg), an active metabolite of psilocybin, in two behavioural paradigms – the open-field test and prepulse inhibition (PPI) of the acoustic startle reaction. Sex differences were evaluated with respect to the phase of the female cycle. The contribution of serotonin receptors in the behavioural action was tested in male rats with selective serotonin receptor antagonists: 5-HT 1A receptor antagonist (WAY100635 1 mg/kg), 5-HT 2A receptor antagonist (MDL100907 0.5 mg/kg), 5-HT 2B receptor antagonist (SB215505 1 mg/kg) and 5-HT 2C receptor antagonist (SB242084 1 mg/kg). Psilocin induced dose-dependent inhibition of locomotion and suppression of normal behaviour in rats (behavioural serotonin syndrome, impaired PPI). The effects were more pronounced in male rats than in females. The inhibition of locomotion was normalized by 5-HT 1A and 5-HT 2B/C antagonists; however, PPI was not affected significantly by these antagonists. Our findings highlight an important issue of sex-specific reactions to psilocin and that apart from 5-HT 2A-mediated effects 5-HT 1A and 5-HT 2C/B receptors also play an important role. These findings have implications for recent clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484 · cited 1×
“However, compared with other hallucinogens, they have inconsistent effects on sensorimotor processing: psilocybin increased the startle response in rats up to doses of 2 mg/kg, but decreased it at doses higher than 4 mg/kg (Davis and Walters, 1977; Geyer et al., 2001; Halberstadt and Geyer, 2011).”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Evolving Knowledge of Sex Differences in Brain Structure, Function, and Chemistry
Cosgrove, K. P., Mazure, C. M., & Staley, J. K. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.001 · Cited by 996 · cited 1×
“These observations could be explained by sex steroidmediated/dependent differences in the serotonin system (Cyr et al., 2000; Birzniece et al., 2002; Zhou et al., 2002; Cosgrove et al., 2007; Sumner et al., 2007).”
BackgroundPrediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
Vollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305 · cited 1×
“In line with this, psilocin has been shown to induce dopamine release in the striatum in humans (Vollenweider et al., 1999) and, more recently, also in the nucleus accumbens of male Wistar rats, although only with a very high dose of 10 mg/kg of psilocin (Sakashita et al., 2015).”
BackgroundHalberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110388326 · Cited by 213
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131 · cited 1×
“According to ligand-binding studies, psilocin has a higher affinity to these receptors than to 5-HT2A receptors (Blair et al., 2000; Ray, 2010; Halberstadt and Geyer, 2011).”
BackgroundSakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81 · cited 1×
“Congruently, 5-HT1A agonism at postsynaptic receptors has been shown to induce some signs of the behavioural serotonin syndrome (e.g. head waving, forepaw treading or flat body posture) (Smith and Peroutka, 1986; Sanchez et al., 1996; Halberstadt and Geyer, 2011).”
BackgroundPáleníček, T., Balíková, M., Bubeníková-Valešová, V., & Horáček, J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-0926-5 · Cited by 61
Self-citation
Cited by
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517
Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
Foldi, C. J., Liknaitzky, P., Williams, M., & Oldfield, B. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00043 · Cited by 51
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Buzzelli, V., Carbone, E., Manduca, A., Schiavi, S., Feo, A., Perederiy, J. V., Ambert, K. H., Hausman, M., & Trezza, V. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06286-3 · Cited by 22
“Studies with high doses of psilocin, an active metabolite of psilocybin, showed behavioral impairments in rats (Sakashita et al. 2015; Tyls et al. 2016), including worsened learning performance in the Morris Water Maze test (Rambousek et al.”
Background
Metadata
- Authors
- Tylš, F., Páleníček, T., Kadeřábek, L., Lipski, M., Kubešová, A., & Horáček, J.
- Venue
- Behavioural Pharmacology
- Published
- 2016-06
- Volume
- 27
- Issue
- 4
- Pages
- 309-320
- ISSN
- 0955-8810 (ISSN-L)
- OpenAlex
- W2318447563
- Cited by
- 86
- References
- 9
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. https://app.cochat.ai/papers/10.1097/fbp.0000000000000198
- The paper
- Tylš, F., Páleníček, T., Kadeřábek, L., Lipski, M., Kubešová, A., & Horáček, J. (2016). Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.